Reference
Drug Index
150 drugs listed — 41 with available data. Greyed out = no data yet.
Data for each drug refer exclusively to patients treated with that drug combined with SBRT,
without concurrent use of drugs from other classes. Combination therapy data are available on each drug group page.
Drug category
A
16
ADV/HSV-tk plus valacyclovir
Gene Therapy
Abemaciclib
CDK4/6 inhibitor
Adagrasib
KRAS Inhibitors
Afamitresgene Autoleucel
CAR-T or Cell Therapy
Afatinib
EGFR targeting TKI
Aflibercept
VEGF-trap
Alectinib
ALK targeting TKI
Alpelisib
PI3K inhibitor
Amivantamab
anti-EGFR/MET mAb
Apatinib
VEGFR targeting TKI
Atezolizumab
Anti-PD-(L)1 mAb
Avapritinib
Multi-target TKI
Avelumab
Anti-PD-(L)1 mAb
Avutometinib
RAF–MEK clamp
Axitinib
Multi-target TKI
alisertib
Aurora A kinase inhibitor
B
5
BMS-986156
anti-GITR mAb
Belzutifan
HIF-2α inhibitor
Bevacizumab
VEGF mAb
Binimetinib
MEK inhibitor
Brigatinib
ALK targeting TKI
C
13
CDX-301
Cytokine Modulators
Cabiralizumab
anti-CSF1R mAb
Cabozantinib
Multi-target TKI
Camrelizumab
Anti-PD-(L)1 mAb
Capivasertib
AKT inhibitor
Capmatinib
MET targeting TKI
Catumaxomab
BiTE
Cemiplimab
Anti-PD-(L)1 mAb
Ceritinib
ALK targeting TKI
Cetuximab
Anti-EGFR mAb
Cobimetinib
MEK inhibitor
Cosibelimab
Anti-PD-(L)1 mAb
Crizotinib
Multi-target TKI
D
10
Dabrafenib
BRAF inhibitor
Dacomitinib
EGFR targeting TKI
Datopotamab Deruxtecan
ADC
Defactinib
FAK/Pyk2 inhibitor
Denosumab
Anti-RANKL mAb
Dinutuximab
anti-GD2 mAb
Dordaviprone
ClpP protease activator
Dostarlimab
Anti-PD-(L)1 mAb
Durvalumab
Anti-PD-(L)1 mAb
dendritic cell vaccine
Therapeutic Vaccines
E
7
Encorafenib
BRAF inhibitor
Enfortumab Vedotin
ADC
Ensartinib
ALK targeting TKI
Entrectinib
Multi-target TKI
Erdafitinib
FGFR targeting TKI
Erlotinib
EGFR targeting TKI
Everolimus
mTOR
F
2
Fruquintinib
VEGFR targeting TKI
Futibatinib
FGFR targeting TKI
G
2
GVAX
Therapeutic Vaccines
Gefitinib
EGFR targeting TKI
I
6
IM-101
Therapeutic Vaccines
Icotinib
EGFR targeting TKI
Inavolisib
PI3K inhibitor
Infigratinib
FGFR targeting TKI
Ipilimumab
Anti-CTLA-4 mAb
Ivosidenib
IDH inhibitor
L
7
Lanreotide
Somatostatin analog
Lapatinib
Multi-target TKI
Larotrectinib
TRK targeting TKI
Lazertinib
EGFR targeting TKI
Lenvatinib
Multi-target TKI
Lifileucel
CAR-T or Cell Therapy
Lorlatinib
ALK targeting TKI
M
5
Margetuximab
anti-HER2 mAb
Mifamurtide
Cytokine Modulators
Mirvetuximab Soravtansine
ADC
Mobocertinib
EGFR targeting TKI
Mogamulizumab
anti-CCR4 mAb
N
11
Nab-Sirolimus
mTOR
Nadofaragene Firadenovec
Gene Therapy
Naxitamab
anti-GD2 mAb
Necitumumab
Anti-EGFR mAb
Neratinib
HER(2) targeting TKI
Nilotinib
Multi-target TKI
Nintedanib
Multi-target TKI
Niraparib
PARP inhibitor
Nirogacestat
Gamma-secretase inhibitor
Nivolumab
Anti-PD-(L)1 mAb
Nogapendekin alfa inbakicept
Cytokine Modulators
P
11
Palbociclib
CDK4/6 inhibitor
Panitumumab
Anti-EGFR mAb
Pazopanib
Multi-target TKI
Peginterferon Alfa-2b
Cytokine Modulators
Pembrolizumab
Anti-PD-(L)1 mAb
Pemigatinib
FGFR targeting TKI
Penpulimab
Anti-PD-(L)1 mAb
Pertuzumab
anti-HER2 mAb
Pertuzumab + hyaluronidase
anti-HER2 mAb
Pertuzumab + trastuzumab + hyaluronidase
anti-HER2 mAb
Pralsetinib
RET targeting TKI
R
10
Racotumomab
Anti-idiotype vaccine mAb
Ramucirumab
VEGF mAb
Regorafenib
Multi-target TKI
Relatlimab
Anti-LAG-3 mAb
Repotrectinib
Multi-target TKI
Retifanlimab
Anti-PD-(L)1 mAb
Ribociclib
CDK4/6 inhibitor
Ripretinib
Multi-target TKI
Rucaparib
PARP inhibitor
Ruxolitinib
JAK inhibitor
S
12
Sacituzumab Govitecan
ADC
Selpercatinib
RET targeting TKI
Serplulimab
Anti-PD-(L)1 mAb
Sevabertinib
HER(2) targeting TKI
Sintilimab
Anti-PD-(L)1 mAb
Sipuleucel-T
Therapeutic Vaccines
Sonidegib
Hedgehog Pathway Inhibitors
Sorafenib
Multi-target TKI
Sotorasib
KRAS Inhibitors
Sugemalimab
Anti-PD-(L)1 mAb
Sunitinib
Multi-target TKI
Sunvozertinib
EGFR targeting TKI
T
20
Talazoparib
PARP inhibitor
Taletrectinib
ROS1 targeting TKI
Talimogene Laherparepvec
Oncolytic virus
Tarlatamab
BiTE
Tazemetostat
EZH2 inhibitor
Tebentafusp
BiTE
Telisotuzumab vedotin
ADC
Temsirolimus
mTOR
Tepotinib
MET targeting TKI
Tislelizumab
Anti-PD-(L)1 mAb
Tisotumab Vedotin
ADC
Tivozanib
VEGFR targeting TKI
Toripalimab
Anti-PD-(L)1 mAb
Tovorafenib
BRAF inhibitor
Trametinib
MEK inhibitor
Trastuzumab
anti-HER2 mAb
Trastuzumab Deruxtecan
ADC
Trastuzumab Emtansine
ADC
Tremelimumab
Anti-CTLA-4 mAb
Tucatinib
HER(2) targeting TKI
U
1
Urelumab
CD137 agonist mAb
V
5
Vandetanib
Multi-target TKI
Vemurafenib
BRAF inhibitor
Vimseltinib
CSF1R targeting TKI
Vismodegib
Hedgehog Pathway Inhibitors
Vorasidenib
IDH inhibitor
Z
4
Zanidatamab
anti-HER2 mAb
Zenocutuzumab
anti-HER2 mAb
Zolbetuximab
anti-claudin 18.2 mAb
Zongertinib
HER(2) targeting TKI